Core Viewpoint - Shengxiang Biotechnology's stock closed at 18.78 yuan, down 1.93%, with a rolling PE ratio of 42.01 times and a total market value of 10.881 billion yuan [1] Company Summary - Shengxiang Biotechnology focuses on in vitro diagnostic solutions, integrating R&D, production, sales of diagnostic reagents and instruments, and third-party medical testing services [1] - The company's main products include a series of products for viral hepatitis, reproductive tract infections, pediatric infections, respiratory infections, nucleic acid blood screening, and more [1] - For the third quarter of 2024, the company reported revenue of 1.033 billion yuan, a year-on-year increase of 63.24%, and a net profit of 195 million yuan, a year-on-year decrease of 34.80%, with a gross margin of 77.50% [1] Industry Summary - The average PE ratio for the medical device industry is 46.40 times, with a median of 34.81 times, placing Shengxiang Biotechnology at the 83rd position in the industry [1][2] - As of the third quarter of 2024, four institutions hold shares in Shengxiang Biotechnology, with a total of 638,900 shares valued at 14 million yuan [1]

序号股票简称PE(TTM)PE(静)市净率总市值(元)87圣湘生物42.4842.481.52110.03亿行业平均 45.9448.384.71101.41亿行业中值29.6428.792.3545.52亿1天益医疗-2672.56-2672.561.6719.88亿2硕世生 物-1835.15-1835.151.1537.91亿3诺唯赞-549.11-549.112.5299.35亿4博晖创新-335.30-206.443.6951.46亿5康 泰医学-262.5830.812.6851.07亿6华大基因-197.28215.792.04200.47亿7奥精医疗-108.26-108.261.3819.61亿 8睿昂基因-79.59-79.591.2411.51亿9热景生物-60.65-60.653.33108.69亿10华大智造-52.74-52.743.96315.97 亿11中红医疗-48.32-32.870.7743.02亿 股东方面，截至2024年9月30日，圣湘生物股东户数19842户，较上次减少461户，户均持股市值35.28万 元，户均持股数量2.76万股。 4月16日，圣湘生物今日收盘1 ...